Most Popular Stories
- AMIA 09: CHCF president calls for more 'Kaiserness' to connect information
- Electronic claims submission could save $11B per year
- Study: Current EMRs don't have measurable impact on cost or quality
- SPOTLIGHT: Hello Health and online doctor visits
- Wal-Mart will market electronic medical records system
- Humana slammed after posting 65 percent increase in third quarter profits
Featured Jobs
-
Family Practice Job in Indiana
StaffPointe, LLC - west central, IN -
Nurse Practitioner Job for Minnesota
StaffPointe, LLC - Twin Cities, MN -
Psychiatry Job in Wisconsin
StaffPointe, LLC - near Wausau, WI -
Physical Therapist
Makro Health - Erie, PA -
ARNP or PA Ortho-Neuro-Spine
MRI of St Petersburg - St. Petersburg, FL
Events
- Security Audits: Is Your Organization Prepared and In Compliance?
Dec.3 at 12 pm CT - Harvard Business School 7th Healthcare Conference
January 30, 2010
Paid Research Reports
- Pricing and Reimbursement in Key Asia Pacific Markets
- Delivery Mechanisms for Large Molecule Drugs: Successes and failures of leading technologies and key drivers for market success
- The Cardiovascular Market Outlook to 2013: Competitive landscape, global market analysis and pipeline analysis
- Intellectual Property and Outsourcing in China: Minimizing risk whilst maximizing return on investment
- Health Care Equipment & Supplies: Global Industry Guide
- 2009 Trends to Watch: Healthcare Technology
FEATURES >> YouTube | Top acute-care hospitals | Women in Health IT | Top BlackBerry Apps | Commentary
TOPICS >> Stimulus | Health Reform | CMS News | Finance | EMRs | Mobile Healthcare | Hospital Leadership Blog
Free Newsletter
FierceHealthcare is the leading source of healthcare management news for healthcare industry executives. Join 46,000+ healthcare industry insiders who get FierceHealthcare via daily email. Sign up today!
Popular Topics
- Medicare
- health plans
- Centers for Medicare and Medicaid Services (CMS)
- Insurance
- Electronic Medical Records (EMRs)
- Food and Drug Administration (FDA)
- Department of Health and Human Services (HHS)
- Medicaid
- American Medical Association (AMA)
- healthcare system
- prescription drugs
- health reform
- pharmaceutical companies
Merck stops lobbying for mandated HPV vaccine
Under pressure from varied interest groups, Merck has agreed to stop lobbying state legislatures in an effort to get them to mandate the HPV vaccine for young girls. Through a third party, Merck had been funding a campaign to have states require the its HPV vaccine Gardasil for 11- and 12-year-old girls before they could attend school. And the drugmaker's efforts had been bearing fruit. Though no bill has passed yet, legislatures in 20 states are considering measures that would institute this requirement.
Despite this legislative success, however, Merck has faced strong opposition to its efforts. Some parent groups had objected to the new requirement, arguing that a drug protecting against a sexually-transmitted disease could lead to teen promiscuity. Also, medical groups like the American Academy of Pediatricians have objected to the campaign, arguing that the campaign is premature at best. They suggest that governments need more time to find funding sources, and parents need more time to learn about the vaccine, which protects against cervical cancer by preventing HPV infections.
To learn more about the Gardasil controversy:
- check out the company's press release
- read this Associated Press article
ALSO: Though about 500 cases of Gardasil side effects have been reported to date--largely minor ones--the CDC doesn't believe any additional warning labels are necessary. Article
Related Articles:
FDA staffers raise Gardasil questions. Report
Merck's Gardasil faces critical new hurdle. Report
Related Stories
- Liquid Tamiflu shortage puts pressure on pharmacists, parents
- FDA, CDC track accidental opioid overdoses
- Cervical cancer vaccine used by 25 percent of girls 13 to 17
- ALSO NOTED: FDA sending fewer warning letters;IL law would limit what hospitals can charge uninsured patients; and much more...
- Merck agrees to $58M settlement on Vioxx ads
- ALSO NOTED: Tenet reports $31M loss for quarter; FDA rules against broader Fentora use; and much more...
- Reports suggest that Merck downplayed Vioxx risks
- Merck drug, suicide linked?
- Vytorin, Avandia raise doubt on FDA approvals
- Statin drug probably not going OTC
Comments
Physicians have to deal with patients who don't want to pay their bills and insurance companys who take weeks to reimburse them for their services. I wonder how many Physicians are actually breaking even on providing this expensive vaccine?
Post new comment
Home
| Subscribe | Advertise | Mobile Edition | RSS |
Privacy
| Site Map | List in Marketplace | Supplier MarketplaceTHE FIERCEMARKETS NETWORKFierceFinance | FierceFinanceIT | FierceComplianceIT | FierceHealthcare | FierceHealthFinance | FierceHealthIT | Hospital Impact | FierceMobileHealthcare | FierceCIO | FierceCIO:TechWatch | FierceContentManagement | FierceMobileIT | FierceGovernmentIT | FierceBiotech | FierceBiotech Research | FiercePharma | FierceVaccines | FierceBiotechIT | FiercePharma Manufacturing | FierceIPTV | FierceOnlineVideo | FierceTelecom | FierceVoIP | FierceBroadbandWireless | FierceDeveloper | FierceMobileContent | FierceWireless | FierceWireless:Europe© 2009 FierceMarkets, Inc. All rights reserved. |
![]() |





